Class Action Lawsuit Against Pacira BioSciences: Important Deadlines for Shareholders

Recent Developments in the Pacira BioSciences Class Action Lawsuit

In a significant development for shareholders, Levi & Korsinsky, LLP has announced crucial information regarding a class action lawsuit that may impact investors of Pacira BioSciences, Inc. (NASDAQ: PCRX). The firm represents investors who have suffered losses due to alleged securities fraud that occurred between August 2, 2023 and August 8, 2024. Shareholders must act quickly, as the deadline to file a lead plaintiff motion is March 14, 2025.

Lawsuit Background

The lawsuit emerges from troubling disclosures made by Pacira on August 9, 2024. Following a court ruling, Pacira stated that the U.S. Patent No. 11,033,495 related to its product Exparel, which constitutes a major portion of its revenue, was invalidated. This particular patent generates nearly 80% of the company's total revenue, and the ruling indicates that eVenus—an opposing party—did not infringe on it.

Due to this disappointing legal outcome, the stock market reacted sharply. Pacira's stock price plummeted from $22.36 per share on August 8 to a devastating $11.70 per share the next day, marking a staggering drop of over 47%. Such dramatic volatility has drawn the attention of shareholders who believe they have grounds for recovery due to losses connected to these events.

Steps for Affected Investors

According to Levi & Korsinsky, affected investors who wish to participate in the lawsuit must be proactive by the deadline mentioned earlier. Even if an investor does not wish to assume the role of the lead plaintiff, they may still recover any potential losses without incurring upfront legal fees. Furthermore, the firm assures that there’s no cost or obligation for participation, making it accessible for all aggrieved shareholders.

In light of the recent developments, those interested in joining the case are encouraged to visit the law firm's website or contact them directly. Engage with experienced securities litigation professionals who have successfully represented numerous clients in past cases.

The Role of Levi & Korsinsky

With over 20 years of experience, Levi & Korsinsky is recognized as a leading firm in securities litigation, having secured substantial settlements for investors. With a dedicated team of over 70 professionals, the firm has earned a reputation for handling high-stakes legal challenges and achieving positive outcomes for their clients. The firm's commitment to shareholder advocacy has propelled it into the Top 50 Report by ISS Securities Class Action Services for seven consecutive years, confirming its standing in the industry.

For inquiries or to find out more about your legal rights regarding this class action, reach out to:

Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500

Conclusion

As the deadline approaches, those impacted by these unfortunate events at Pacira BioSciences are advised to review their potential eligibility for compensation. This situation underscores the importance of vigilance among investors and their rights within the complex landscape of securities laws. Those feeling uncertain should not hesitate to seek legal counsel to navigate these waters effectively.